Age-Specific Infant Formula With HMOs for Lactation Stages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing infant formulas do not adequately mimic the changing composition of human milk throughout different lactation stages, leading to disparities in gut and immune system development between breastfed and formula-fed infants.
Innovation Solution
Development of age-specific infant formulas containing varying ratios and amounts of 3'-sialyllactose, 3-fucosyllactose, and difucosyllactose to match the human milk oligosaccharide composition at different lactation stages, specifically for infants aged 0-4 months, 4-8 months, and 8-36 months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a single infant formula composition is used throughout infancy, then manufacturing and distribution is simplified, but it cannot adequately mimic the changing composition of human milk throughout different lactation stages
Solution Approach 1:
The patent segments the infant formula market into distinct lactation stages (0-6 months, 6-12 months, 12-24 months, 24-36 months), with each stage having a specifically formulated composition. This segmentation allows the formula to adapt to changing nutritional needs at different ages while maintaining manageable complexity through standardized formulations for each stage.
Solution Approach 2:
The patent implements dynamic adaptation by adjusting formula composition to match human milk composition at different lactation stages. The formula transitions from closely mimicking early milk (high protein, high fat) in the first 6 months to progressively altering composition to reflect later milk stages, thereby dynamically adapting to infant developmental needs.
2Quantity of substance
If infant formula composition remains constant, then production and storage is easier, but it fails to provide stage-specific nutrition that mimics human milk changes
Solution Approach 1:
The patent applies parameter changes by systematically adjusting key nutritional parameters (protein content, fat content, carbohydrate composition, vitamin levels, mineral content) across different lactation stages. Each stage-specific formula contains optimized parameter values that reflect human milk composition at that stage, thereby achieving accurate stage-specific nutrition through controlled parameter variations.
3Reliability
If human milk oligosaccharides are added to infant formula, then gut and immune system development is improved, but the formula composition becomes more complex and costly
Solution Approach 1:
The patent applies local quality by incorporating specific human milk oligosaccharides (HMOs) such as 2'-fucosyllactose, lacto-N-neotetraose, and 3'-sialyllactose at stage-specific concentrations. Each lactation stage formula contains HMOs at levels that reflect human milk composition at that stage, providing targeted gut and immune support appropriate to the infant's developmental needs without uniformly complicating all formulas.
Data Source
Figure 1
AI summary
The present invention relates to the field of infant nutrition. Particularly, the present invention relates to infant formula comprising human milk oligosaccharides wherein the infant formula is specific for infants aged 0-36 months at different lactation stages. The invention also relates to lactation stage specific systems and methods of providing nutrition to an infant.